Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NMB_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NMB_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NMB_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NMB_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NMB_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00329435 | Cervix | CC | mononuclear cell proliferation | 59/2311 | 291/18723 | 7.51e-05 | 1.03e-03 | 59 |
GO:19019873 | Cervix | CC | regulation of cell cycle phase transition | 74/2311 | 390/18723 | 9.80e-05 | 1.27e-03 | 74 |
GO:1903038 | Cervix | CC | negative regulation of leukocyte cell-cell adhesion | 33/2311 | 141/18723 | 1.90e-04 | 2.21e-03 | 33 |
GO:0050866 | Cervix | CC | negative regulation of cell activation | 44/2311 | 210/18723 | 2.76e-04 | 3.02e-03 | 44 |
GO:00016497 | Cervix | CC | osteoblast differentiation | 47/2311 | 229/18723 | 2.88e-04 | 3.11e-03 | 47 |
GO:190121410 | Cervix | CC | regulation of neuron death | 61/2311 | 319/18723 | 3.11e-04 | 3.31e-03 | 61 |
GO:00703714 | Cervix | CC | ERK1 and ERK2 cascade | 60/2311 | 330/18723 | 1.28e-03 | 1.02e-02 | 60 |
GO:00015037 | Cervix | CC | ossification | 71/2311 | 408/18723 | 1.67e-03 | 1.28e-02 | 71 |
GO:00457862 | Cervix | CC | negative regulation of cell cycle | 67/2311 | 385/18723 | 2.21e-03 | 1.59e-02 | 67 |
GO:0070664 | Cervix | CC | negative regulation of leukocyte proliferation | 21/2311 | 90/18723 | 2.71e-03 | 1.85e-02 | 21 |
GO:00459302 | Cervix | CC | negative regulation of mitotic cell cycle | 44/2311 | 235/18723 | 3.02e-03 | 1.99e-02 | 44 |
GO:19019912 | Cervix | CC | negative regulation of mitotic cell cycle phase transition | 35/2311 | 179/18723 | 3.73e-03 | 2.38e-02 | 35 |
GO:19013423 | Cervix | CC | regulation of vasculature development | 60/2311 | 348/18723 | 4.48e-03 | 2.72e-02 | 60 |
GO:00487712 | Cervix | CC | tissue remodeling | 34/2311 | 175/18723 | 4.68e-03 | 2.82e-02 | 34 |
GO:00457653 | Cervix | CC | regulation of angiogenesis | 59/2311 | 342/18723 | 4.73e-03 | 2.83e-02 | 59 |
GO:00703723 | Cervix | CC | regulation of ERK1 and ERK2 cascade | 54/2311 | 309/18723 | 5.11e-03 | 3.02e-02 | 54 |
GO:0050672 | Cervix | CC | negative regulation of lymphocyte proliferation | 19/2311 | 83/18723 | 5.25e-03 | 3.08e-02 | 19 |
GO:0032945 | Cervix | CC | negative regulation of mononuclear cell proliferation | 19/2311 | 84/18723 | 6.02e-03 | 3.43e-02 | 19 |
GO:20001341 | Cervix | CC | negative regulation of G1/S transition of mitotic cell cycle | 19/2311 | 84/18723 | 6.02e-03 | 3.43e-02 | 19 |
GO:0042130 | Cervix | CC | negative regulation of T cell proliferation | 16/2311 | 67/18723 | 6.51e-03 | 3.61e-02 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NMB | insertion | Frame_Shift_Ins | novel | c.230_231insAGCATATAGTGTGTGCATTTTGAAGGGA | p.Arg78AlafsTer19 | p.R78Afs*19 | P08949 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
NMB | SNV | Missense_Mutation | | c.365C>A | p.Pro122Gln | p.P122Q | P08949 | protein_coding | tolerated_low_confidence(0.25) | benign(0.005) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
NMB | SNV | Missense_Mutation | novel | c.384N>C | p.Gln128His | p.Q128H | P08949 | protein_coding | tolerated_low_confidence(0.21) | benign(0.138) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NMB | SNV | Missense_Mutation | novel | c.418G>T | p.Val140Leu | p.V140L | P08949 | protein_coding | tolerated_low_confidence(0.59) | benign(0.001) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
NMB | SNV | Missense_Mutation | | c.341N>A | p.Gly114Asp | p.G114D | P08949 | protein_coding | tolerated_low_confidence(0.12) | benign(0.058) | TCGA-BS-A0U7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NMB | SNV | Missense_Mutation | | c.406N>A | p.His136Asn | p.H136N | P08949 | protein_coding | tolerated_low_confidence(0.05) | benign(0.015) | TCGA-D1-A0ZS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NMB | SNV | Missense_Mutation | | c.388C>T | p.Arg130Cys | p.R130C | P08949 | protein_coding | tolerated_low_confidence(0.05) | benign(0.003) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NMB | SNV | Missense_Mutation | novel | c.455G>A | p.Cys152Tyr | p.C152Y | P08949 | protein_coding | deleterious_low_confidence(0.02) | benign(0.01) | TCGA-22-1002-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NMB | SNV | Missense_Mutation | novel | c.83G>A | p.Ser28Asn | p.S28N | P08949 | protein_coding | tolerated(0.13) | benign(0.006) | TCGA-CN-5373-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NMB | SNV | Missense_Mutation | novel | c.289G>C | p.Ala97Pro | p.A97P | P08949 | protein_coding | deleterious(0.02) | possibly_damaging(0.735) | TCGA-CR-7364-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |